BOSTON, April 30, 2019 — OM1, a leading health outcomes, data and technology company today announced that its rheumatology registries, which track hundreds of thousands of patients longitudinally throughout the United States, are now available for direct licensing as well as studies and advanced analytics. The registries include: Rheumatoid Arthritis Systemic Lupus Erythematosus Sjögrens Giant[…]
OM1 LUPUS REGISTRY REACHES MORE THAN 25,000 PATIENTS PROSPECTIVELY FOLLOWED WITH DEEP CLINICAL AND LAB DATA Ready for collaborations, the registry enables faster, more cost-effective access to research-grade lupus data for better understanding, comparing, and predicting treatment outcomes BOSTON, October 17, 2018 — OM1, a leading health outcomes, registries and technology company creating solutions to[…]
March 28, 2018 – 2 PM ET What if you could use predictive models like biomarkers to pre-emptively screen and more effectively target patients who are more likely to respond to your drug in trials and in practice? What if you could rapidly answer questions on comparative treatment outcomes and predict those most likely to[…]
November 28, 2017 – Dr. Richard Gliklich As artificial intelligence and advanced analytics are increasingly lauded for uses in life sciences and healthcare, it’s becoming difficult to differentiate between the different terms, to understand what is real and what is hype, and to understand how to best leverage these technologies for advancing real-world evidence and[…]
BIG DATA REVEALS 1 OUT OF 6 ER VISITS IN Q2 2017 OPIOID RELATED OM1 launches a prototype for tracking the public health crisis in near real time BOSTON, November 27, 2017 — OM1, a leading AI health outcomes and data company focused on making healthcare more measured, precise and pre-emptive, today announced it has[…]
